Literature DB >> 29025982

Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors.

Thomas A Hope1,2, Emily K Bergsland3,4, Murat Fani Bozkurt5, Michael Graham6, Anthony P Heaney7, Ken Herrmann5, James R Howe4,8, Matthew H Kulke3,4,9, Pamela L Kunz3,4,9, Josh Mailman10, Lawrence May11, David C Metz4,12, Corina Millo6, Sue O'Dorisio6,3,4, Diane L Reidy-Lagunes3,4, Michael C Soulen4,13, Jonathan R Strosberg3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29025982      PMCID： PMC6910630          DOI： 10.2967/jnumed.117.202275

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  51 in total

1.  68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.

Authors:  Thorsten D Poeppel; Ina Binse; Stephan Petersenn; Harald Lahner; Matthias Schott; Gerald Antoch; Wolfgang Brandau; Andreas Bockisch; Christian Boy
Journal:  J Nucl Med       Date:  2011-11-09       Impact factor: 10.057

2.  The ACR Appropriateness Criteria: view from the committee chair.

Authors:  Michael A Bettmann
Journal:  J Am Coll Radiol       Date:  2006-07       Impact factor: 5.532

3.  Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

Authors:  Jonathan Strosberg; Ghassan El-Haddad; Edward Wolin; Andrew Hendifar; James Yao; Beth Chasen; Erik Mittra; Pamela L Kunz; Matthew H Kulke; Heather Jacene; David Bushnell; Thomas M O'Dorisio; Richard P Baum; Harshad R Kulkarni; Martyn Caplin; Rachida Lebtahi; Timothy Hobday; Ebrahim Delpassand; Eric Van Cutsem; Al Benson; Rajaventhan Srirajaskanthan; Marianne Pavel; Jaime Mora; Jordan Berlin; Enrique Grande; Nicholas Reed; Ettore Seregni; Kjell Öberg; Maribel Lopera Sierra; Paola Santoro; Thomas Thevenet; Jack L Erion; Philippe Ruszniewski; Dik Kwekkeboom; Eric Krenning
Journal:  N Engl J Med       Date:  2017-01-12       Impact factor: 91.245

4.  Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.

Authors:  Laura H Tang; Brian R Untch; Diane L Reidy; Eileen O'Reilly; Deepti Dhall; Lily Jih; Olca Basturk; Peter J Allen; David S Klimstra
Journal:  Clin Cancer Res       Date:  2015-10-19       Impact factor: 12.531

5.  Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.

Authors:  Samira M Sadowski; Vladimir Neychev; Corina Millo; Joanna Shih; Naris Nilubol; Peter Herscovitch; Karel Pacak; Stephen J Marx; Electron Kebebew
Journal:  J Clin Oncol       Date:  2015-12-28       Impact factor: 44.544

6.  Somatostatin-receptor imaging in the localization of endocrine tumors.

Authors:  S W Lamberts; W H Bakker; J C Reubi; E P Krenning
Journal:  N Engl J Med       Date:  1990-11-01       Impact factor: 91.245

7.  Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated.

Authors:  Nitya Raj; Emily Valentino; Marinela Capanu; Laura H Tang; Olca Basturk; Brian R Untch; Peter J Allen; David S Klimstra; Diane Reidy-Lagunes
Journal:  Pancreas       Date:  2017-03       Impact factor: 3.327

Review 8.  Changing paradigms with molecular imaging of neuroendocrine tumors.

Authors:  Michael S Hofman; Rodney J Hicks
Journal:  Discov Med       Date:  2012-07       Impact factor: 2.970

9.  Role of IV iodinated contrast material in 18F-FDG PET/CT of liver metastases.

Authors:  Shiva Badiee; Benjamin L Franc; Emily M Webb; Bill Chu; Randall A Hawkins; Fergus Coakley; Lisa Singer
Journal:  AJR Am J Roentgenol       Date:  2008-11       Impact factor: 3.959

10.  QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies.

Authors:  Penny F Whiting; Anne W S Rutjes; Marie E Westwood; Susan Mallett; Jonathan J Deeks; Johannes B Reitsma; Mariska M G Leeflang; Jonathan A C Sterne; Patrick M M Bossuyt
Journal:  Ann Intern Med       Date:  2011-10-18       Impact factor: 25.391
View more
  46 in total

Review 1.  Somatostatin receptor PET ligands - the next generation for clinical practice.

Authors:  Elin Pauwels; Frederik Cleeren; Guy Bormans; Christophe M Deroose
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-10-20

Review 2.  Carcinoid Tumors: Past, Present, and Future.

Authors:  James R Howe
Journal:  Indian J Surg Oncol       Date:  2020-05-09

3.  The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors.

Authors:  James R Howe; Nipun B Merchant; Claudius Conrad; Xavier M Keutgen; Julie Hallet; Jeffrey A Drebin; Rebecca M Minter; Terry C Lairmore; Jennifer F Tseng; Herbert J Zeh; Steven K Libutti; Gagandeep Singh; Jeffrey E Lee; Thomas A Hope; Michelle K Kim; Yusuf Menda; Thorvardur R Halfdanarson; Jennifer A Chan; Rodney F Pommier
Journal:  Pancreas       Date:  2020-01       Impact factor: 3.327

4.  Small Bowel Neuroendocrine Tumors.

Authors:  Catherine G Tran; Scott K Sherman; James R Howe
Journal:  Curr Probl Surg       Date:  2020-05-15       Impact factor: 1.909

5.  High Interobserver Agreement for the Standardized Reporting System SSTR-RADS 1.0 on Somatostatin Receptor PET/CT.

Authors:  Rudolf A Werner; Thorsten Derlin; Steven P Rowe; Lena Bundschuh; Gabriel T Sheikh; Martin G Pomper; Sebastian Schulz; Takahiro Higuchi; Andreas K Buck; Frank M Bengel; Ralph A Bundschuh; Constantin Lapa
Journal:  J Nucl Med       Date:  2020-08-28       Impact factor: 10.057

6.  111In-Pentetreotide Scintigraphy Versus 68Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden.

Authors:  Thomas A Hope; Jeremie Calais; Li Zhang; William Dieckmann; Corina Millo
Journal:  J Nucl Med       Date:  2019-03-08       Impact factor: 10.057

7.  Prognostic value of somatostatin receptor expressing tumor volume calculated from 68Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors.

Authors:  Akira Toriihara; Lucia Baratto; Tomomi Nobashi; Sonya Park; Negin Hatami; Guido Davidzon; Pamela L Kunz; Andrei Iagaru
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-27       Impact factor: 9.236

Review 8.  Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2018-07-17       Impact factor: 4.512

9.  Prospective comparison of whole-body MRI with diffusion-weighted and conventional imaging for the follow-up of neuroendocrine tumors.

Authors:  Maximilien Minon; Clothilde Soriano; David Morland; Thomas Walter; Côme Lepage; Antoine Tabarin; Mathilde Deblock; Pascal Rousset; Coralie Barbe; Christine Hoeffel; Guillaume Cadiot
Journal:  Endocrine       Date:  2019-09-28       Impact factor: 3.633

Review 10.  Workup of Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Joseph S Dillon
Journal:  Surg Oncol Clin N Am       Date:  2020-04       Impact factor: 3.495
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.